EP3863611A1 - Method for manufacturing a solid formulation for oral administration, associated facility and solid formulation - Google Patents
Method for manufacturing a solid formulation for oral administration, associated facility and solid formulationInfo
- Publication number
- EP3863611A1 EP3863611A1 EP19783547.3A EP19783547A EP3863611A1 EP 3863611 A1 EP3863611 A1 EP 3863611A1 EP 19783547 A EP19783547 A EP 19783547A EP 3863611 A1 EP3863611 A1 EP 3863611A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- liquid formulation
- manufacturing
- formulation
- substrate
- film
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 107
- 238000009472 formulation Methods 0.000 title claims abstract description 76
- 239000007787 solid Substances 0.000 title claims abstract description 62
- 238000000034 method Methods 0.000 title claims abstract description 57
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 45
- 239000000758 substrate Substances 0.000 claims abstract description 61
- 239000012669 liquid formulation Substances 0.000 claims abstract description 57
- 238000005507 spraying Methods 0.000 claims abstract description 44
- 239000004480 active ingredient Substances 0.000 claims abstract description 26
- 238000005259 measurement Methods 0.000 claims abstract description 23
- 239000002904 solvent Substances 0.000 claims abstract description 22
- 230000001066 destructive effect Effects 0.000 claims abstract description 9
- 238000001704 evaporation Methods 0.000 claims abstract description 8
- 239000008186 active pharmaceutical agent Substances 0.000 claims abstract description 7
- 239000008247 solid mixture Substances 0.000 claims abstract description 6
- 238000007639 printing Methods 0.000 claims description 34
- 238000009434 installation Methods 0.000 claims description 20
- 239000007921 spray Substances 0.000 claims description 20
- 230000008569 process Effects 0.000 claims description 17
- 238000004806 packaging method and process Methods 0.000 claims description 9
- 239000000796 flavoring agent Substances 0.000 claims description 6
- 235000019634 flavors Nutrition 0.000 claims description 6
- 229920002678 cellulose Polymers 0.000 claims description 5
- 239000001913 cellulose Substances 0.000 claims description 5
- 230000008020 evaporation Effects 0.000 claims description 4
- 229920003169 water-soluble polymer Polymers 0.000 claims description 4
- 230000003556 anti-epileptic effect Effects 0.000 claims description 3
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 3
- 239000001961 anticonvulsive agent Substances 0.000 claims description 3
- 239000000739 antihistaminic agent Substances 0.000 claims description 3
- 230000002159 abnormal effect Effects 0.000 claims description 2
- 229940035676 analgesics Drugs 0.000 claims description 2
- 239000000730 antalgic agent Substances 0.000 claims description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 2
- 229960003965 antiepileptics Drugs 0.000 claims description 2
- 229940125715 antihistaminic agent Drugs 0.000 claims description 2
- 239000011814 protection agent Substances 0.000 claims description 2
- 239000003688 hormone derivative Substances 0.000 claims 1
- 230000009471 action Effects 0.000 description 32
- 238000001035 drying Methods 0.000 description 14
- 238000004458 analytical method Methods 0.000 description 11
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- 238000005520 cutting process Methods 0.000 description 8
- 239000003814 drug Substances 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 6
- 230000001960 triggered effect Effects 0.000 description 6
- 102100036958 Cytosolic Fe-S cluster assembly factor NUBP1 Human genes 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 5
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 5
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 5
- 238000007789 sealing Methods 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 230000000996 additive effect Effects 0.000 description 4
- 235000010980 cellulose Nutrition 0.000 description 4
- 239000005022 packaging material Substances 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 3
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000000151 deposition Methods 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 3
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 3
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 3
- 230000011664 signaling Effects 0.000 description 3
- 238000011144 upstream manufacturing Methods 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 108010000437 Deamino Arginine Vasopressin Proteins 0.000 description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 2
- 238000004497 NIR spectroscopy Methods 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000010418 carrageenan Nutrition 0.000 description 2
- 229920001525 carrageenan Polymers 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- 230000001955 cumulated effect Effects 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 229960004281 desmopressin Drugs 0.000 description 2
- NFLWUMRGJYTJIN-NXBWRCJVSA-N desmopressin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSCCC(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(N)=O)=O)CCC(=O)N)C1=CC=CC=C1 NFLWUMRGJYTJIN-NXBWRCJVSA-N 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 238000001192 hot extrusion Methods 0.000 description 2
- 238000009776 industrial production Methods 0.000 description 2
- 238000007641 inkjet printing Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000002952 polymeric resin Substances 0.000 description 2
- 229920002689 polyvinyl acetate Polymers 0.000 description 2
- 239000011118 polyvinyl acetate Substances 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 238000011057 process analytical technology Methods 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 230000007781 signaling event Effects 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000004611 spectroscopical analysis Methods 0.000 description 2
- 238000003892 spreading Methods 0.000 description 2
- 230000007480 spreading Effects 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 229920003002 synthetic resin Polymers 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- JLTCWSBVQSZVLT-CDIPANDDSA-N (2s)-n-[(2s)-6-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxohexan-2-yl]-1-[(4r,7s,10s,13s,16s,19r)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosan Chemical compound NCCCC[C@@H](C(=O)NCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](N)CSSC1.C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 JLTCWSBVQSZVLT-CDIPANDDSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- 238000010146 3D printing Methods 0.000 description 1
- PXRKCOCTEMYUEG-UHFFFAOYSA-N 5-aminoisoindole-1,3-dione Chemical compound NC1=CC=C2C(=O)NC(=O)C2=C1 PXRKCOCTEMYUEG-UHFFFAOYSA-N 0.000 description 1
- GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 description 1
- 101710139687 Cytosolic Fe-S cluster assembly factor NUBP1 Proteins 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 229920001218 Pullulan Polymers 0.000 description 1
- 238000001069 Raman spectroscopy Methods 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000003929 acidic solution Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 239000003637 basic solution Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 229920003090 carboxymethyl hydroxyethyl cellulose Polymers 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 238000000701 chemical imaging Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 238000010924 continuous production Methods 0.000 description 1
- 238000004320 controlled atmosphere Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- IINNWAYUJNWZRM-UHFFFAOYSA-L erythrosin B Chemical compound [Na+].[Na+].[O-]C(=O)C1=CC=CC=C1C1=C2C=C(I)C(=O)C(I)=C2OC2=C(I)C([O-])=C(I)C=C21 IINNWAYUJNWZRM-UHFFFAOYSA-L 0.000 description 1
- 235000012732 erythrosine Nutrition 0.000 description 1
- 229940011411 erythrosine Drugs 0.000 description 1
- 239000004174 erythrosine Substances 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000002864 food coloring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 150000002605 large molecules Chemical class 0.000 description 1
- 238000003698 laser cutting Methods 0.000 description 1
- 238000010147 laser engraving Methods 0.000 description 1
- RDOIQAHITMMDAJ-UHFFFAOYSA-N loperamide Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)N(C)C)CCN(CC1)CCC1(O)C1=CC=C(Cl)C=C1 RDOIQAHITMMDAJ-UHFFFAOYSA-N 0.000 description 1
- 229960001571 loperamide Drugs 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000003232 mucoadhesive effect Effects 0.000 description 1
- 229920001206 natural gum Polymers 0.000 description 1
- 238000002095 near-infrared Raman spectroscopy Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 238000001139 pH measurement Methods 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000002985 plastic film Substances 0.000 description 1
- 229920006255 plastic film Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 235000019423 pullulan Nutrition 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000009517 secondary packaging Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000010215 titanium dioxide Nutrition 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/095—Oxytocins; Vasopressins; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
- A61J3/005—Coating of tablets or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
- A61J3/06—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of pills, lozenges or dragees
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7007—Drug-containing films, membranes or sheets
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B41—PRINTING; LINING MACHINES; TYPEWRITERS; STAMPS
- B41F—PRINTING MACHINES OR PRESSES
- B41F17/00—Printing apparatus or machines of special types or for particular purposes, not otherwise provided for
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65B—MACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING
- B65B3/00—Packaging plastic material, semiliquids, liquids or mixed solids and liquids, in individual containers or receptacles, e.g. bags, sacks, boxes, cartons, cans, or jars
- B65B3/003—Filling medical containers such as ampoules, vials, syringes or the like
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65B—MACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING
- B65B31/00—Packaging articles or materials under special atmospheric or gaseous conditions; Adding propellants to aerosol containers
- B65B31/04—Evacuating, pressurising or gasifying filled containers or wrappers by means of nozzles through which air or other gas, e.g. an inert gas, is withdrawn or supplied
- B65B31/046—Evacuating, pressurising or gasifying filled containers or wrappers by means of nozzles through which air or other gas, e.g. an inert gas, is withdrawn or supplied the nozzles co-operating, or being combined, with a device for opening or closing the container or wrapper
- B65B31/048—Evacuating, pressurising or gasifying filled containers or wrappers by means of nozzles through which air or other gas, e.g. an inert gas, is withdrawn or supplied the nozzles co-operating, or being combined, with a device for opening or closing the container or wrapper specially adapted for wrappers or bags
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65B—MACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING
- B65B35/00—Supplying, feeding, arranging or orientating articles to be packaged
- B65B35/30—Arranging and feeding articles in groups
- B65B35/44—Arranging and feeding articles in groups by endless belts or chains
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65B—MACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING
- B65B51/00—Devices for, or methods of, sealing or securing package folds or closures; Devices for gathering or twisting wrappers, or necks of bags
- B65B51/10—Applying or generating heat or pressure or combinations thereof
- B65B51/26—Devices specially adapted for producing transverse or longitudinal seams in webs or tubes
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65B—MACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING
- B65B57/00—Automatic control, checking, warning, or safety devices
- B65B57/10—Automatic control, checking, warning, or safety devices responsive to absence, presence, abnormal feed, or misplacement of articles or materials to be packaged
- B65B57/14—Automatic control, checking, warning, or safety devices responsive to absence, presence, abnormal feed, or misplacement of articles or materials to be packaged and operating to control, or stop, the feed of articles or material to be packaged
- B65B57/145—Automatic control, checking, warning, or safety devices responsive to absence, presence, abnormal feed, or misplacement of articles or materials to be packaged and operating to control, or stop, the feed of articles or material to be packaged for fluent material
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65B—MACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING
- B65B57/00—Automatic control, checking, warning, or safety devices
- B65B57/18—Automatic control, checking, warning, or safety devices causing operation of audible or visible alarm signals
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65B—MACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING
- B65B59/00—Arrangements to enable machines to handle articles of different sizes, to produce packages of different sizes, to vary the contents of packages, to handle different types of packaging material, or to give access for cleaning or maintenance purposes
- B65B59/001—Arrangements to enable adjustments related to the product to be packaged
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65B—MACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING
- B65B61/00—Auxiliary devices, not otherwise provided for, for operating on sheets, blanks, webs, binding material, containers or packages
- B65B61/02—Auxiliary devices, not otherwise provided for, for operating on sheets, blanks, webs, binding material, containers or packages for perforating, scoring, slitting, or applying code or date marks on material prior to packaging
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65B—MACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING
- B65B61/00—Auxiliary devices, not otherwise provided for, for operating on sheets, blanks, webs, binding material, containers or packages
- B65B61/02—Auxiliary devices, not otherwise provided for, for operating on sheets, blanks, webs, binding material, containers or packages for perforating, scoring, slitting, or applying code or date marks on material prior to packaging
- B65B61/025—Auxiliary devices, not otherwise provided for, for operating on sheets, blanks, webs, binding material, containers or packages for perforating, scoring, slitting, or applying code or date marks on material prior to packaging for applying, e.g. printing, code or date marks on material prior to packaging
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65B—MACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING
- B65B61/00—Auxiliary devices, not otherwise provided for, for operating on sheets, blanks, webs, binding material, containers or packages
- B65B61/04—Auxiliary devices, not otherwise provided for, for operating on sheets, blanks, webs, binding material, containers or packages for severing webs, or for separating joined packages
- B65B61/06—Auxiliary devices, not otherwise provided for, for operating on sheets, blanks, webs, binding material, containers or packages for severing webs, or for separating joined packages by cutting
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65B—MACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING
- B65B9/00—Enclosing successive articles, or quantities of material, e.g. liquids or semiliquids, in flat, folded, or tubular webs of flexible sheet material; Subdividing filled flexible tubes to form packages
- B65B9/02—Enclosing successive articles, or quantities of material between opposed webs
- B65B9/026—Enclosing successive articles, or quantities of material between opposed webs the webs forming a curtain
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D65/00—Wrappers or flexible covers; Packaging materials of special type or form
- B65D65/38—Packaging materials of special type or form
- B65D65/46—Applications of disintegrable, dissolvable or edible materials
- B65D65/463—Edible packaging materials
Definitions
- the present invention relates to a method of manufacturing a solid formulation for oral administration, said solid formulation comprising a portion of edible substrate on which is deposited a first composition comprising a first active pharmaceutical ingredient, said method comprising the following steps: supplying the substrate edible in film form; supply of a first liquid formulation comprising the first pharmaceutical active ingredient and a solvent; then spraying the first liquid formulation onto the film and evaporating the solvent, so as to form the first solid composition deposited on the substrate.
- the invention is particularly applicable to solid formulations comprising an orodispersible film.
- Oral pharmaceutical forms of orodispersible films are known in particular from documents EP3281625 and US2017216220. Such pharmaceutical forms are produced in particular by spreading on a support a solution comprising a pharmaceutical active ingredient and polymers, drying the solution leading to the production of a film.
- Such production methods are suitable for producing drugs in large quantities, with a uniform dosage.
- a technical problem linked to the industrial production of oral pharmaceutical forms by printing is in particular the control of the dose of active principle in each pharmaceutical form produced.
- EP3403643 A1 relates in particular to the design of compositions comprising an active principle. It discloses measurements made on prototypes of such compositions in order to validate the content. However, it does not disclose any measurement which would be carried out on an active ingredient contained in the result of a spraying carried out using such a composition.
- the present invention aims to allow the industrial production of custom drugs for oral administration.
- the tests carried out show that the drugs thus obtained have a stability (and therefore a conservation) of at least six months.
- the present invention involves spraying liquids onto surfaces in order to obtain the desired compositions by drying. It involves controlling the amounts sprayed.
- predetermined quantity or reference quantity to designate a target quantity (quantity that we seek to obtain), and we also denote such quantity by the term of "value" ("predetermined value” and “Reference value” being synonymous with “predetermined quantity” and “reference quantity”).
- the subject of the invention is a manufacturing process of the aforementioned type, and more particularly a manufacturing process of a solid formulation for oral administration, said solid formulation comprising a portion of edible substrate on which is deposited a first composition comprising a first principle pharmaceutical active, said method comprising the following steps:
- Said manufacturing process also includes the following steps:
- each portion supports a quantity (which may be denoted Q for a portion considered) of first active principle corresponding to a value predetermined (can be noted Q ref ); in other words, the spraying according to the method is adjusted so that the quantity Q resulting therefrom comes as close as possible to a value predetermined Q re f desired (ie "corresponds" to this predetermined value Qref); and
- Said comparison makes it possible to trigger an action (or several actions). It makes it possible to take corrective measures such as the destruction of the portions of which the quantity of active principle is too far from the predetermined value, or, if this quantity is insufficient, the spraying of an additional quantity on this same portion in order to avoid its destruction.
- Said comparison also makes it possible (alternately and cumulatively) to check the spraying setting, and if necessary, either to report a setting problem (for example by triggering an alert via an audible or visual alarm, or sending a e-mail alert), either to carry out an automatic adjustment of the adjustment, or both, that is to say both to report an adjustment problem and to adjust it automatically.
- This comparison is made by an electronic device, such as a processor, a microcontroller, an on-board computer, or dedicated electronics.
- the method comprises one or more of the following characteristics, taken in isolation or in any technically possible combination:
- this reporting is carried out by an electronic device, such as a processor, a microcontroller, a on-board computer, or dedicated electronics);
- step of adjusting the spray setting as a function of said comparison is made by an electronic device, such as a processor, a microcontroller, an on-board computer, or dedicated electronics;
- the first liquid formulation has a viscosity between 2 mPa.s and 20 mPa.s; and / or a surface tension between 20 mN / m and 50 mN / m, or even, according to a particular implementation, between 25 mN / m and 50 mN / m;
- the first active ingredient in the first liquid formulation is chosen from analgesics, antihistamines, anti-inflammatories, anti-epileptics and natural, synthetic or biotechnological hormones;
- the first liquid formulation further comprises a dye
- the edible substrate comprises one or more water-soluble polymers, preferably one or more cellulose derivatives,
- a step of spraying the first liquid formulation onto a first zone of each portion of film the method further comprising the following steps: supplying a second liquid formulation comprising a second solvent; said second liquid formulation preferably comprising a second active pharmaceutical ingredient and / or a flavor; then spraying the second liquid formulation onto a second zone of the film and evaporation of the second solvent, so as to form a second solid composition deposited on the substrate, the first and second zones of the film being distinct from one of the other.
- the invention also relates to a solid formulation for oral administration, resulting from a process as described above, said formulation comprising a portion of edible substrate on which is deposited at least one composition comprising an active pharmaceutical ingredient.
- the invention further relates to an installation for continuously manufacturing a solid formulation for oral administration, suitable for implementing a method as described above, said installation comprising: a device for supplying the substrate edible in the form of a film strip, said strip being configured to be divided into a plurality of portions (whether by a complete or discontinuous cutting of each portion, a discontinuous cutting, in the form for example of dotted precut, allowing later to easily separate such a portion); a device for printing the first liquid formulation; a control device connected to the printing device, said control device being capable of implementing the printing of a predetermined quantity of first liquid formulation on each portion of substrate; and a device for non-destructive measurement of a quantity of first active principle supported by each portion; the control device being provided with means for comparing the quantity measured with a predetermined value (corresponding to the quantity predetermined, the mathematical "value" representing the physical "quantity” and designating the same reality) of first liquid formulation.
- the manufacturing installation further comprises an individual packaging device for each solid formulation.
- Figure 1 is a schematic representation of solid formulations according to a first, a second and a third embodiment of the invention
- FIG. 2 is a schematic representation of a manufacturing facility according to an embodiment of the invention, for making the solid formulations of Figure 1;
- Figure 3 is a detail view of an edible substrate that can be used in the installation of Figure 2;
- Figure 4 is a flow diagram representing the steps of a manufacturing process, according to one embodiment of the invention, of the solid formulations of Figure 1.
- FIG. 1 represents a first 10, a second 40 and a third 60 solid formulations for oral administration, respectively according to a first, a second and a third embodiment of the invention.
- the spraying is controlled by a spraying command, this command receiving as input a setting (or "setting value”, or "amount of setting").
- the initial setting value is fixed at a predetermined value.
- this setting value is, at the start of the process, equal to a predetermined quantity (value) that one wishes to spray.
- the initial setting value is only indexed to this predetermined value in order to be representative. Indeed, it does not matter to use an identical numerical value for the initial adjustment and for the predetermined value, it only matters to allow the interpretation of the numerical value used as adjustment value in order to be able to determine that its value whatever it is, corresponds to the predetermined value and to interpret its subsequent value.
- the quantity sprayed is, according to a possible implementation, determined by a spraying setting equal to the resolution (which may be denoted RES) of printing.
- RES the resolution
- each resolution corresponds to a quantity sprayed and vice versa.
- the higher the resolution the more dots are printed, and therefore the greater the quantity sprayed.
- the resolution of the print can be adjusted in number of dots printed per unit of distance (for example in dots per inch, unit designated by the acronym DPI), the same resolution can be used in both directions of printing (in case of 2D printing).
- the spray setting is then a RES parameter (such as a resolution of 350 DPI), this parameter corresponding to a predetermined quantity to be sprayed.
- the setting optionally includes (in addition to a RES resolution) a number of NBP passes.
- the process prints NBP-1 times the same surface with a maximum resolution and prints a NBP th time this surface with the resolution RES indicated in the setting, in order to increase the maximum sprayable quantity.
- the setting, for a predetermined value VP can be initially set to the integer closest to the value (2 N -1) * (VP-VP min ) / (VPmax-VP min ).
- a predetermined value of 400 mg would lead to an initial spraying setting equal to:
- a value N greater than 10 allows the spray setting to be represented with fairly fine precision.
- the solid formulation 10, 40, 60 comprises a substrate 12 and a first composition 14 deposited on said substrate.
- the solid formulation 40, 60 further comprises a second composition 16 deposited on the substrate 12.
- the substrate 12 is an edible substrate, in the form of a film 18.
- the substrate 12 is an orodispersible substrate.
- the substrate 12 does not comprise any active principle.
- the substrate 12 has a pH adapted to the active principle, so as to improve the conservation of the active principle over time.
- the substrate 12 is obtained in particular from one or more excipient (s) making it possible to modify the pH, such as citric acid or dilute phosphoric acid (as illustrated below) after in the formulation examples), to obtain an acid pH.
- excipients can be used to obtain a basic pH.
- the substrate 12 comprises one or more water-soluble polymers.
- said water-soluble polymers are chosen from: cellulose derivatives, such as hydroxypropyl cellulose (HPC), hydroxypropyl methyl cellulose (HPMC), sodium carboxymethyl cellulose (CMC-Na) or hydroxyethyl cellulose (HEC) ); polyvinyl derivatives such as polyvinylpyrrolidone (PVP), poly (vinyl acetate) (PVA) or PVP-PVA copolymers; natural gums such as Xanthan or gum arabics; alginates, especially sodium alginates; carrageenan gums, such as iota or lambda carrageenans; starches, such as corn starch, pea starch, or pregelatinized starches; pectins with high degrees of esterification; type B gelatins; dextrins; the pullulans.
- HPC hydroxypropyl cellulose
- HPMC hydroxypropyl methyl cellulose
- the substrate 12 comprises one or more cellulose derivatives such as hydroxypropyl cellulose, hydroxypropyl methyl cellulose, sodium carboxymethyl cellulose or hydroxyethyl cellulose.
- the substrate 12 also comprises a flavor and / or a sweetener, natural like fructose or synthetic like potassium acesulfame.
- the substrate 12 further comprises a salivary stimulant, such as citric or malic acid; or talc (Mg 3 Si 4 Oio (OH) 2 ) and / or a dye such as titanium oxide (not privileged given its possible carcinogenic nature).
- a salivary stimulant such as citric or malic acid
- talc Mg 3 Si 4 Oio (OH) 2
- a dye such as titanium oxide (not privileged given its possible carcinogenic nature).
- the film 18 forming the substrate 12 preferably has a thickness of between 80 ⁇ m and 500 ⁇ m, and preferably between 80 ⁇ m and 120 ⁇ m, but, according to a possible implementation, between 200 ⁇ m and 500 ⁇ m. According to one embodiment, the film 18 is designed to dissolve in a patient's mouth in less than three minutes or, in an advantageous case, in less than 30 seconds.
- the substrate 12 comprises a first 20 and a second opposite faces, delimited by a contour 22. Only the first face 20 is visible in FIG. 1.
- the contour 22 defines a surface 24 of the substrate 12.
- the surface 24 is chosen so as to allow the oral absorption of the solid formulation 10, 40, 60 in a single take.
- the surface 24 is for example between 0, 5 cm 2 and 10 cm 2 .
- the outline 22 has a square shape whose sides have a length of about 2 cm.
- the contour 22 can adopt other shapes, for example rectangular, polygonal, round or oval.
- the surface 24 has a first zone 26, 46, 66 on which the first composition 14 is deposited.
- the first composition 14 comprises in particular a first pharmaceutical active ingredient.
- the invention relates mainly to active compounds at relatively low concentrations, so that they can be reached by spraying a small amount of liquid composition onto a substrate.
- the invention relates mainly to compounds soluble in water or in low toxic solvents.
- the first composition is limited to the first active principle, to the exclusion of any other product (excipient, etc.).
- the first active ingredient is for example an analgesic, an antihistamine, an anti-inflammatory, an antiepileptic or a natural, synthetic or biotechnological hormone.
- the first active ingredient can be chosen from a wide range of compounds including small and large molecules.
- the first active ingredient is a peptide such as desmopressin (1-desamino-8-d-arginine vasopressine).
- the first composition 14 also comprises a first dye, which makes it possible to visualize with the naked eye its deposit on the substrate 12, and which also allows, upstream, a dosage by colorimetry.
- the first color is for example chosen from food colors such as Erythrosine or Sunset Yellow.
- the first zone 26, 46, 66 is arranged on the first face 20 of the substrate 12.
- the first zone 26, 46 has a square or rectangular shape.
- the first area 66 has a substantially annular shape, delimiting a central space 67.
- Other shapes can be envisaged for the first area, said shapes corresponding for example to a visual representation or to a decorative pattern.
- Each of the second and third solid formulations 40, 60 further comprises a second zone 48, 68 on which the second composition 16 is deposited.
- the second composition 16 comprises for example a second pharmaceutical active principle and / or a flavor, said flavor being for example chosen from the flavors used in the food industry.
- the second composition 16 also includes a second dye, which makes it possible to visualize with the naked eye its deposit on the substrate 12.
- the first 46, 66 and second 48, 68 zones are preferably distinct from each other, that is to say not superimposed. More preferably, a space 30 is provided between said first 46, 66 and second 48, 68 zones. This is advantageous in that it makes it possible to avoid migration of the products between the different zones (their possible mixing could otherwise lead to a reduction in the storage period).
- the first 46 and second 48 zones are arranged side by side.
- the first and second zones are arranged around one another.
- the second zone 68 is arranged in the central space 67 delimited by the first zone 66.
- the second zone 48, 68 is located on the first face 20 of the substrate 12, as is the first zone 46, 66.
- the first and second zones are arranged on two opposite faces of the substrate 12.
- the deposition of the first 14 and second 16 compositions on two zones away from one another eliminates the risk of chemical interaction between said compositions, which improves the stability of the solid formulation 40, 60.
- the solid formulation comprises at least three compositions, preferably deposited on three distinct zones of the substrate.
- each of the first 14 and second 16 compositions is formed by spraying, onto the substrate 12, micro-droplets of a liquid formulation comprising a solvent, then by evaporation of said solvent.
- the first 14 and second 16 compositions therefore comprise all of the components of the corresponding liquid formulations, with the exception of the volatile components.
- it is a piezoelectric device which performs this spraying.
- it is for example a thermal device. But in the latter case, only active ingredients which cannot be degraded by the Heating of the thermal device can be used, and the spraying is often less precise.
- micro-droplets drops of a size which can vary between 10 12 L and 10 ⁇ 6 L approximately.
- FIG. 2 represents an installation 100 allowing the manufacture of a solid formulation 10, 40, 60 as described above.
- the installation 100 includes a set of juxtaposed devices, each of said devices allowing the implementation of a step of a process for manufacturing the solid formulation 10, 40, 60. Such a process will be described later.
- the installation 100 includes in particular: a device 102 for supplying film 18; a printing device 104; a drying device 106; an analysis device 108; a sorting device 110 and a packaging device 111.
- the film 18 is obtained by hot extrusion or 3D printing of a polymer resin.
- the installation 100 further comprises an electronic control unit 112, such as a computer, connected to said devices.
- the control unit 112 contains a program 114 allowing the implementation of the manufacturing process described later.
- the supply device 102 comprises a strip 120 of film 18, partially shown in FIG. 3.
- a device for manufacturing the film 18 is directly connected to the supply device 102.
- the manufacturing device implements the step of dividing the film 18 into a plurality of portions by manufacturing a divided film (for example a precut film).
- the film 18 is for example obtained by hot extrusion of a polymer resin, or by spreading such a resin on a support, followed by drying.
- the strip 120 is wound on itself around an axis in the form of a roll 122.
- the roll 122 further comprises a support tape 124 co-wound with the strip 120
- the supply device 102 further comprises means for unwinding the roll 122.
- the roller is replaced by a set of sheets distributed by a feeder.
- the unwound strip 120 extends mainly in a longitudinal direction X, as well as in a transverse direction Y.
- the terms “entry”, “exit”, “upstream”, “downstream” are relating to the installation 100 are understood in the longitudinal direction X.
- the strip 120 is precut into portions 12, each portion being intended to form the substrate 12 of the solid formulation 10, 40, 60. At the start of the process, the portions 12 are joined together by the presence of the support tape 124.
- the portions 12 of the strip 120 are aligned in the longitudinal X and transverse directions Y.
- the strip 120 comprises, for example, between three and a hundred aligned portions 12.
- the printing device 104 comprises a first 130 and a second 132 printing modules, respectively intended to deposit the first 14 and the second 16 compositions on the substrate 12.
- Each printing module 130, 132 comprises: a printing head 134; a tank 136; a conduit 138 connecting said head to said reservoir; and a pump 140 disposed on said conduit.
- the reservoir 136 of each of the first 130 and second 132 printing modules respectively contains a first 144 and a second 146 liquid formulations, making it possible respectively to obtain the first 14 and the second 16 compositions.
- the reservoir 136 is provided with a device for agitating the liquid formulation.
- the manufacture of the liquid formulation 144, 146 is carried out directly in the reservoir 136, shortly before the start-up of the printing device 104.
- the first liquid formulation comprises a pH regulator, so as to improve the conservation of the active principle.
- the pH regulator is incorporated into the first liquid formulation, for example during its preparation, and at the latest when filling the reservoir with the first liquid formulation ).
- the pH regulator is added to the liquid formulation present in the reservoir 136 following a measurement of the pH (for example using a pH probe placed in this tank).
- a pump or other injection device is activated to add an appropriate volume of acidic or basic solution capable of correcting the pH.
- the method applies a pH adjustment technique similar to any of those described below for adjusting the spray setting (using one or more pH thresholds, which can represent positive or negative deviations from the desired pH, each threshold being able to trigger an adjustment action).
- the print head 134 of each of the first 130 and second 132 print modules is capable of projecting microdroplets of liquid formulation 144, 146 onto the film 18.
- the print head 134 is preferably a print head. thermal or piezoelectric inkjet type printing, more preferably piezoelectric.
- Such printheads are sold in particular by the companies Konica Minolta and Fujifilm Dimatix.
- each printing module further comprises a buffer tank, interposed between the conduit 138 and the printing head 134. Said printing head is directly connected to the buffer tank.
- the liquid formulation 144, 146 comprises at least one solvent and optionally excipients.
- the at least one solvent of the liquid formulation 144, 146 is preferably little or not toxic, for example of class 3 ICH.
- the at least one solvent of the liquid formulation 144, 146 preferably has a low boiling point, in order to evaporate easily after printing.
- the at least one solvent comprises for example water and / or ethanol.
- the at least one solvent further comprises dimethylsulfoxide (DMSO) for better solubilization of the compounds.
- DMSO dimethylsulfoxide
- the viscosity of the first 144 and / or of the second 146 liquid formulation is between 2 mPa.s and 20 mPa.s, more preferably between 2 mPa.s and 10 mPa.s.
- the surface tension of the first 144 and / or of the second 146 liquid formulation is between 20 mN / m and 50 mN / m, and, according to a possible implementation, between 25 mN / m and 50 mN / m.
- the first 144 and / or the second 146 liquid formulation preferably comprises an additive to modify its viscosity and / or its surface tension, such as propylene glycol.
- first 144 and / or the second 146 liquid formulation preferably comprises a pH regulating additive, chosen according to the characteristics of stability of the active ingredient. It can be an acid additive such as acetic acid, or a basic additive.
- the installation 100 comprises a conveyor 150 capable of receiving the strip 120 of film; and optionally a rotary roller 152 allowing the support tape 124 to be wound up to dissociate it from said strip 120.
- the installation further comprises a device for cutting the strip between the drying device and the analysis device.
- the conveyor 150 comprises for example an endless belt 154 extending between two drive rollers.
- the drying device 106 is arranged on the path of the conveyor 150.
- Said drying device 106 is of the oven type and comprises a heating element such as an electrical resistance, or an infrared radiating element.
- the analysis device 108 is also arranged on the path of the conveyor 150, downstream of the drying device 106 and above the endless belt 154.
- the analysis device 108 is able to measure a quantity of first active ingredient supported by the substrate 12 of a solid formulation 10, 40, 60, said measurement being non-destructive of said formulation.
- the analysis device 108 preferably comprises an electromagnetic spectroscopy device, of the near infrared spectroscopy type (NIR spectroscop ⁇ ), or Raman spectroscopy, or a hyperspectral imaging device. All these devices implement in a known manner measures which are non-destructive insofar as they only subject the active principle to spectroscopy (which in principle does not last more than a minute), which does not alter it not. Other types of measurement are also possible, such as weighing by a precision balance and more generally technologies called PAT ("Process Analytical Technologies").
- the measurements carried out which determine a (precise) quantity of active principle, make it possible to compare this quantity with a reference value and thus to assess the difference between the desired quantity (reference value) and the real quantity.
- the measurement is carried out once the drying of the sprayed liquid formulation is substantial, so that the quantity of solvent still present is small and falsifies the measurement as little as possible. Even more advantageously, the measurement is carried out after a complete drying step. Indeed, the tests carried out have shown that the more advanced the drying, the more the measurement accuracy is improved. Drying stabilizes the formulation and increases its concentration.
- the method calculates the difference between the quantity measured and the reference value in relative form E r (for example in the form of a percentage).
- the method calculates this difference in an absolute form E a , for example by volume or by mass, expressed for example in microliters (pL) or in milligrams (mg), or in any other appropriate unit.
- the method defines a threshold from which the amount of active ingredient is considered to be inaccurate.
- This threshold can be expressed in relative form S r , for example using a percentage (such as: SF1, 5%).
- the method when the method demonstrates that the difference between the quantity of active principle measured in a given portion deviates from the reference value by more than the threshold (for example, more than 1.5% deviation E r , or more than 3 ⁇ l deviation E a , or more than 4 mg deviation E a ), it triggers an action.
- the threshold for example, more than 1.5% deviation E r , or more than 3 ⁇ l deviation E a , or more than 4 mg deviation E a
- the process triggers an action as soon as the quantity exceeds 406 mg or drops below 394 mg (i.e. 1.5% above or below 400 mg).
- the process triggers an action as soon as the quantity exceeds 404 mg or drops below 396 mg.
- this action consists in triggering an action for adjusting the spraying.
- the adjustment consists in modifying the resolution (expressed for example in DPI, ie in number of dots per inch) of the spraying device (which can be close to inkjet printer technologies) .
- the adjustment can be made more generally by modifying a spray control. If the threshold has been exceeded upwards, the spraying is reduced for the subsequent stages of continuous manufacturing (ie for the following portions - and not for the portion which has been the subject of the measurement which triggered the adjustment action ). Likewise, if the threshold has been exceeded downwards, the spraying is increased for the subsequent stages of continuous production.
- this action consists in sorting the portion having given rise to an inaccurate measurement.
- This sorting consists for example of routing the portions whose measurement is inaccurate towards a receptacle which can be eliminated when it is full (destruction).
- the process may, instead of discard this portion, pass it again through a spraying step in order to complete the amount of active ingredient and bring it closer to the reference value.
- this action consists in signaling the existence of a deviation via an electronic alert device (leading for example to light a red LED, to display a message in the form of text or pictogram, to sound an alarm, send an automatic email, etc.).
- the alarm is triggered continuously, as long as the measurements do not return within the limit defined by the threshold. This alarm can be cumulated with the sorting action (and if necessary a renewed spraying) and can also be cumulated with the spraying adjustment action.
- the method defines several thresholds, different actions being able to be triggered according to the crossed thresholds.
- the method comprises a low threshold which triggers a first action, and a high threshold which triggers a second action.
- These thresholds can be relative or absolute.
- the relative low threshold is 1.5% and the only relative high is 10%
- the absolute low threshold is 4 mg and the only absolute high is 20 mg.
- the choice of the threshold value depends on the active ingredient and may depend on personalized parameters (age, sex, height, weight, medical history, etc.). This choice can be made by a person qualified in pharmacy and thus lead to a definition of different thresholds for each of the many possible configurations.
- the method is then arranged to automatically select the relevant threshold or thresholds thus defined according to input data (active ingredient, age, sex, height, weight, medical history, etc.).
- the method comprises means for manual entry of the threshold (s), the latter replacing the automatic selection (if the latter is implemented), which is thus deactivated by manual entry.
- the first action is a signaling (alarm) action when the low threshold is exceeded.
- the first action is a spray adjustment action (already described).
- exceeding the low threshold triggers the two aforementioned actions (signaling and adjusting the spraying).
- the second action is a signaling action (alarm) for exceeding the high threshold, which may be different from the signaling action (alarm) for exceeding the low threshold (in order to mark the increased importance of this alarm).
- the second action is a sorting action and, where appropriate, additional spraying (already described).
- exceeding the high threshold triggers the two aforementioned actions (reporting and sorting, plus possibly additional spraying).
- the method defines a different threshold upward and downward (in fact, the overdose and underdosing of a drug do not necessarily have the same consequences).
- the method defines, according to a possible implementation, a low upper threshold and a high upper threshold, as well as a low lower threshold and a high lower threshold.
- Each of these thresholds can be relative or absolute.
- the alarm can be different so that an operator is informed of the direction of overshoot, or else the adjustment can be different (for example faster in the event of overshoot by overdose only by overrun by underdosing, or vice versa).
- the alarm can be different so that an operator is informed of the direction of overshoot, or even, as already mentioned, the sorting can be different (it can lead to throwing a overdosed portion, but trying to "fix" an underdosed portion rather than throwing it away).
- the method continuously implements an action for adjusting the spray setting, without verifying that the threshold has been exceeded.
- the method implements a feedback loop, consisting of subtracting from the spray setting value, to be submitted as an input parameter to the subsequent spray command, a percentage of the difference between the quantity measured and the reference value (and thus subject the modified setting resulting from this subtraction to the spraying command). This percentage can take various values. The higher the percentage, the faster the correction, but the greater the risk of overcorrection (and generating a deviation in the other direction). The lower the percentage, the slower the adjustment, but the less it risks generating parasitic oscillations.
- the spray setting is (at least initially) equal to the reference value
- the percentage is set to 30%
- the reference value is set to 200 mg
- the quantity measured is 210 mg
- the difference E a is 10 mg.
- the process then sends the sprayer an instruction to spray 3 mg less (-30% of 10 mg).
- the quantity measured for example 207 mg
- the process sends the sprayer a setpoint of spray 2.1 mg less (-30% of 7 mg).
- the method changes, during iterations, the spray adjustment value, in order to bring the measured value (at the end of the spray) closer to the reference value.
- the process adjusts (according to a possible implementation) the setting value in proportion to the deviation observed. For example, if the measured value is 10% lower than the reference value, and if the percentage applied for the adjustment is (as above) by 30%, the setting value is increased by 30% by 11, 11% ie 3.33% (NB for a value which is 10% below normal to return to normal, it must be increased by 11, 11%). For a non-linear adjustment value relative to the measured quantity, it is possible to apply an appropriate non-linear adjustment (ie different from the aforementioned proportional adjustment).
- an action for adjusting the spray setting is only triggered in response to a threshold being exceeded.
- the measured quantity must then be sufficiently different from the predetermined value for an adjustment to start.
- This adjustment can be a feedback loop as described in the previous paragraph. But it can also be another type of correction.
- the method can adjust the spraying control by a constant value less than or equal to the threshold (and not by a percentage of the difference). Indeed, it is assumed that the difference is greater than or equal to this constant value.
- no adjustment of the spraying adjustment takes place.
- the adjustment is carried out once and for all at the start of each production, and the comparison of the measured quantity and the reference value is then not used to trigger an adjustment (but to trigger other actions, for example, a sorting of portions).
- the sorting device 110 is also placed on the path of the conveyor 150, downstream of the analysis device 108.
- the sorting device 110 is able to remove from the conveyor 150 the solid formulations 10, 40, 60 including the analysis results are not satisfactory.
- the sorting device 110 comprises for example a nozzle 156, which blows compressed air or sucks the defective solid formulations 10, 40, 60 in order to remove them from the conveyor 150.
- Such sorting is advantageous because it allows exhaustive control of the manufactured products. Any product resulting from the process is then of adequate quality (since verified). This allows the final product to be released directly at the end of the manufacturing process and deliver it, without waiting (ie without having to implement an additional quality procedure), to patients.
- the packaging device 111 is disposed at the outlet of the conveyor 150. Upstream of the packaging device are arranged two rollers 160, each roller being capable of unwinding a sheet of packaging material 162 of the aluminum foil type covered with plastic film.
- the packaging device 111 includes drive means capable of placing a sheet of packaging material 162 in contact with each of the faces of the solid formulations 10, 40, 60.
- the packaging device 111 comprises an inscription device 164, of the laser engraving or printer type, capable of recording information on the packaging material 162 as it is scrolled.
- the packaging device 111 Downstream of the rollers 160, the packaging device 111 comprises a sealing device 166, capable of fixing the two sheets of packaging material 162 to one another, so as to form a closed compartment 170 around each. solid formulations 10, 40, 60.
- the sealing device 166 comprises for example a heating element.
- the sealing device 166 also comprises means for implementing the sealing under a controlled atmosphere, of the nitrogen type.
- the packaging device 111 Downstream of the sealing device 166, the packaging device 111 comprises a cutting device 168 capable of dissociating from one another the closed compartments 170 containing the solid formulations 10, 40, 60.
- a method 200 of manufacturing a solid formulation 10, 40, 60 will now be described. This process, shown diagrammatically by the flow diagram in FIG. 4, is implemented by the program 114 stored in the electronic control unit 112.
- the strip 120 precut with film 18, disposed on the support tape 124 is presented at the input of the printing device 104 and moves in the longitudinal direction X.
- the printing head 134 of the first printing module 130 deposits, on the first face 20 of each portion 12 of the strip 120, micro-droplets of first liquid formulation 144 (step 204).
- the deposition is carried out on the first zone 26, 46, 66 of each portion 12.
- the quantity of first liquid formulation 144 per portion 12 is managed by the program 114, according to the quantity of first active principle desired (reference quantity) for the solid formulation 10, 40, 60 manufactured.
- the installation 100 is, for example, calibrated before the implementation of the manufacturing process, by carrying out a dosage of the first liquid formulation 144 as the first active principle.
- the print head 134 of the second print module 132 then deposits, on the second zone 48, 68 from each portion 12 of the strip 120, micro-droplets of second liquid formulation 146 (step 206).
- the amount of second liquid formulation 146 per serving 12 is managed by the program 114.
- the support ribbon 124 is wound on the rotary roller 152 and dissociated from the strip 120 of film 18.
- the portions 12 of said strip 120 are received on the conveyor 150 and driven to the drying 106.
- the solvents of the first 144 and second 146 liquid formulations finish evaporating (step 208), leading to the first 14 and second 16 compositions deposited on the substrate 12.
- the solid formulation 10, 40, 60 described above is thus obtained .
- the solid formulations 10, 40, 60 are then driven by the conveyor to the analysis device 108.
- said analysis device measures the quantity Q of first active principle deposited on the substrate 12 (step 210). Said measurement is for example carried out by near infrared spectroscopy or Raman spectroscopy.
- the program 114 compares each measured Q value with a reference value CW, stored in said program (step 212). For example, the program 114 checks whether the value Q is included in a range [CW ⁇ AQ], AQ being a value also stored in said program (corresponding to a single threshold). According to a possible implementation, the program 114 adjusts the spraying setting as a function of the value Q (this is symbolized, in FIG. 4, the inclined arrow pointing from step 212 towards the spraying step 204). In a possible implementation, the program only adjusts the spraying setting if Q moves away from Q ref by more than AQ (whether down or up). According to a variant, one (or more) specific threshold (s) is (are) used. According to another variant, the adjustment is systematic (whatever the value of Q, and therefore independently of any threshold).
- the program 114 identifies each solid formulation 10, 40, 60 as belonging to a first or to a second group, the value Q of which is respectively included and not included in the targeted range.
- the sorting device 110 then removes from the conveyor 150 (step 214) the formulations belonging to said second group.
- the solid formulations 10, 40, 60 remaining on the conveyor 150 therefore all comprise a quantity Q of first active principle included in the range [CW ⁇ AQ],
- the analysis and sorting steps are also carried out on said second active ingredient (step 216).
- Each solid formulation 10, 40, 60 is then individually wrapped by the wrapping device 111 (step 218).
- the registration device 164 records information such as a batch number, an identifier of the first and / or second active ingredient, or a date of manufacture or expiration.
- Solid formulations 10, 40, 60, individually wrapped, are thus recovered at the outlet of the installation 100.
- the method further comprises a secondary packaging step, in which solid formulations 10, 40, 60 individually wrapped are grouped in a container of the cardboard box type.
- the installation 100 and the method 200 described above allow significant flexibility in the production of solid formulations 10, 40, 60.
- the program 114 makes it possible to adjust, vary and control in real time the quantity of first 144 and / or second 146 liquid formulation sprayed on each portion 12 of the strip 120. It is thus easy to successively produce solid formulations 10, 40, 60 corresponding to different dosages, without interrupting production.
- liquid formulation 144, 146 of the printing device 104 it is possible to rapidly modify the liquid formulation 144, 146 of the printing device 104, so as to continuously produce, from the same substrate, solid formulations comprising different active ingredients.
- the installation 100 and the method 200 thus make it possible to produce custom-made medicines easily and at low cost, by adapting the dosage to each patient.
- the strip 120 is supplied precut before the printing step 204.
- the strip 120 supplied is continuous and the method comprises, after the printing step, a step of cutting said strip into a plurality of portions 12.
- said cutting step is carried out before the analysis step 210, 212 and sorting 214.
- the solid formulations 10, 40, 60 are not orodispersible formulations but are intended to be used in the form of buccal patches, muco-adhesive or not. Only the nature of the substrate 12 needs to be modified to achieve this variant.
- the objective is to obtain a flexible and non-brittle substrate 12; slightly acidic pH (4.7-5.0); with low humidity, especially less than 10%; and which dissolves in less than 10 s.
- slightly acidic pH 4.7-5.0
- low humidity especially less than 10%
- dissolves in less than 10 s The following four formulations have been developed:
- the cellulose derivatives represent at least 40% by mass of the dry composition; the acid is preferably used in a proportion of less than 1%.
- the formulation is spread on a flat surface and dried.
- the film 18 is obtained with a thickness of approximately 250 ⁇ m. According to an alternative, it is obtained with a lower thickness, for example 100 ⁇ m or 120 ⁇ m.
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Mechanical Engineering (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Zoology (AREA)
- Dispersion Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1859441A FR3087125B1 (en) | 2018-10-11 | 2018-10-11 | METHOD OF MANUFACTURING A SOLID FORMULATION FOR ORAL ADMINISTRATION, ASSOCIATED INSTALLATION AND SOLID FORMULATION |
PCT/EP2019/077663 WO2020074734A1 (en) | 2018-10-11 | 2019-10-11 | Method for manufacturing a solid formulation for oral administration, associated facility and solid formulation |
Publications (1)
Publication Number | Publication Date |
---|---|
EP3863611A1 true EP3863611A1 (en) | 2021-08-18 |
Family
ID=65244248
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP19783547.3A Pending EP3863611A1 (en) | 2018-10-11 | 2019-10-11 | Method for manufacturing a solid formulation for oral administration, associated facility and solid formulation |
Country Status (14)
Country | Link |
---|---|
US (1) | US20220054582A1 (en) |
EP (1) | EP3863611A1 (en) |
JP (1) | JP2022504797A (en) |
KR (1) | KR20210075124A (en) |
CN (1) | CN113015522A (en) |
AU (1) | AU2019358520A1 (en) |
BR (1) | BR112021006688A2 (en) |
CA (1) | CA3115727A1 (en) |
EA (1) | EA202190958A1 (en) |
FR (1) | FR3087125B1 (en) |
IL (1) | IL282068A (en) |
MX (1) | MX2021004025A (en) |
TW (1) | TW202031246A (en) |
WO (1) | WO2020074734A1 (en) |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1061557A (en) * | 1964-04-01 | 1967-03-15 | Ashe Chemical Ltd | New impregnated or coated films |
ZA767136B (en) * | 1975-12-15 | 1977-10-26 | Hoffmann La Roche | Novel dosage form |
US6623785B2 (en) * | 2001-06-07 | 2003-09-23 | Hewlett-Packard Development Company, L.P. | Pharmaceutical dispensing apparatus and method |
DE102011088909A1 (en) * | 2011-08-12 | 2013-02-14 | Labtec Gmbh | Process for the preparation and control of oral drug films |
KR101547219B1 (en) * | 2014-12-31 | 2015-08-25 | (주)씨엘팜 | Method and apparatus for producing oral dispersible film with multi low and formulated drug |
WO2016163403A1 (en) | 2015-04-07 | 2016-10-13 | ニプロ株式会社 | Oral film preparation |
CL2016000112A1 (en) * | 2016-01-15 | 2016-07-01 | Univ Chile | Pharmaceutical form for oral administration of highly controlled dose. controlled and stable release of biomachromolecule comprising polymeric film as a printing substrate and an injection ink printed on said polymeric film comprising nanoparticles or suspensions of nanoparticles with said biomachromolecule and preparation methods. |
US20170216220A1 (en) | 2016-02-03 | 2017-08-03 | Intelgenx Corp. | Loxapine film oral dosage form |
CN107412177B (en) * | 2017-08-25 | 2020-12-15 | 广东药科大学 | 3D printed hydrochlorothiazide tablet and preparation method thereof |
-
2018
- 2018-10-11 FR FR1859441A patent/FR3087125B1/en active Active
-
2019
- 2019-10-11 CA CA3115727A patent/CA3115727A1/en active Pending
- 2019-10-11 CN CN201980067289.XA patent/CN113015522A/en active Pending
- 2019-10-11 MX MX2021004025A patent/MX2021004025A/en unknown
- 2019-10-11 AU AU2019358520A patent/AU2019358520A1/en active Pending
- 2019-10-11 BR BR112021006688-8A patent/BR112021006688A2/en unknown
- 2019-10-11 EA EA202190958A patent/EA202190958A1/en unknown
- 2019-10-11 EP EP19783547.3A patent/EP3863611A1/en active Pending
- 2019-10-11 WO PCT/EP2019/077663 patent/WO2020074734A1/en unknown
- 2019-10-11 US US17/283,178 patent/US20220054582A1/en active Pending
- 2019-10-11 KR KR1020217013633A patent/KR20210075124A/en unknown
- 2019-10-11 JP JP2021520177A patent/JP2022504797A/en active Pending
- 2019-10-14 TW TW108136905A patent/TW202031246A/en unknown
-
2021
- 2021-04-05 IL IL282068A patent/IL282068A/en unknown
Also Published As
Publication number | Publication date |
---|---|
TW202031246A (en) | 2020-09-01 |
FR3087125B1 (en) | 2021-07-02 |
CN113015522A (en) | 2021-06-22 |
IL282068A (en) | 2021-06-30 |
JP2022504797A (en) | 2022-01-13 |
BR112021006688A2 (en) | 2021-07-27 |
FR3087125A1 (en) | 2020-04-17 |
EA202190958A1 (en) | 2021-07-16 |
WO2020074734A1 (en) | 2020-04-16 |
KR20210075124A (en) | 2021-06-22 |
US20220054582A1 (en) | 2022-02-24 |
MX2021004025A (en) | 2021-08-11 |
AU2019358520A1 (en) | 2021-05-20 |
CA3115727A1 (en) | 2020-04-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Raijada et al. | A step toward development of printable dosage forms for poorly soluble drugs | |
US10092020B2 (en) | Non-contact printed comestible products and apparatus and method for producing same | |
RU2006146063A (en) | DEVICE AND METHOD OF PHARMACEUTICAL PRODUCTION | |
JP2007510796A (en) | System and method for edible optically invisible ink | |
Edinger et al. | Analytical aspects of printed oral dosage forms | |
US8282954B2 (en) | Method for manufacturing edible film | |
WO2009044118A2 (en) | Indelibly marked polymeric films | |
WO2010007312A2 (en) | Method of manufacturing cellular films directly | |
US11648197B2 (en) | Dispensing method for producing dissolvable unit dose film constructs | |
EP3863611A1 (en) | Method for manufacturing a solid formulation for oral administration, associated facility and solid formulation | |
KR101214140B1 (en) | Method and apparatus for synchronizing of production and packing of oral film | |
EA045793B1 (en) | METHOD FOR PRODUCING SOLID COMPOSITION FOR ORAL ADMINISTRATION, ASSOCIATED EQUIPMENT AND SOLID COMPOSITION | |
EP3897588A1 (en) | Sugar-coated solid forms having improved stability | |
WO2018234248A1 (en) | Sugar coating method and sugar coated solid forms with irregular shapes | |
US7900577B2 (en) | System and a method for starch-based, slow-release oral dosage forms | |
WO2005089698A1 (en) | Pharmaceutical dispensing apparatus | |
FR2521450A1 (en) | PROCESS AND APPARATUS FOR THE PRODUCTION OF PERFECTLY SPHERICAL AND POROUS PELLETS AND PELLETS FOR THE PHARMACEUTICAL INDUSTRY THUS OBTAINED | |
Ahmed | Effects of different polymers on thermal inkjet printing of oral thin films: a novel approach | |
US20050203482A1 (en) | Pharmaceutical dispensing apparatus and method | |
Visser | Orodispersible films as pharmacy preparations: Let’s get flexible | |
US20160199293A1 (en) | Method for manufacturing an ingestible film, apparatus for manufacturing an ingestible film, ingestible film and pharmaceutical dosage form comprising the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20210506 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
P01 | Opt-out of the competence of the unified patent court (upc) registered |
Effective date: 20230403 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20240613 |
|
17Q | First examination report despatched |
Effective date: 20240625 |